COMTYour two copies: rs4680A/rs4680A
Decreased function
Both copies work less well.
Breaks down dopamine and other brain chemicals.
This result changes the label.
Example report. The whole genome example: a public genome from the 1000 Genomes Project, with CYP2D6 Structural Analysis, so you can see what yours will look like. Get your own report
Other substancesExample report
MDMA
Ecstasy
Use with caution
Your genotype has been linked to more dizziness, anxiety and sedation after MDMA, and to a larger drop in blood sodium.
The genes behind this label
The guidelines read 2 genes for MDMA. Each card shows the two copies this person inherited and what they mean.
CYP2D6Your two copies: *2/*2x2
Ultrarapid metabolizer
One copy works normally and one works faster than usual.
3.0 activity scoreTypical: 1.25 to 2.25Turns on or clears about 1 in 4 prescription drugs. These include many drugs for depression, pain and ADHD.
This result doesn't change the label.
What the guidelines say
What each guideline says about your result.
COMTDecreased function
Gene2Rx research summary
Use with caution Evidence: weakSee the drug page (Gene2Rx research summaries, opens in a new tab)
- In plain words
- Your genotype has been linked to more dizziness, anxiety and sedation after MDMA, and to a larger drop in blood sodium.
- What it means
- Two rs4680 A alleles (Met158/Met158), the lower-activity form. In a controlled study, lower-activity COMT genotypes were associated with more negative subjective effects after MDMA, specifically dizziness, anxiety and sedation. In a field study of clubbers, low-activity COMT genotypes were associated with larger falls in plasma sodium and osmolality, the mechanism behind MDMA-related dilutional hyponatraemia.
- What the research suggests
- If exposure occurs, monitor neurological and cardiovascular status and fluid intake. Both supporting studies are small and unreplicated.
CYP2D6Ultrarapid metabolizer
Gene2Rx research summary
Use as directed See the drug page (Gene2Rx research summaries, opens in a new tab)
- In plain words
- You may clear this drug faster than average. No dose change is suggested for your result.
- What it means
- Increased CYP2D6 activity, so faster O-demethylenation of MDMA is expected. No study has examined MDMA in ultrarapid metabolizers. This result cannot be produced from uploaded consumer array or sequencing data, because increased-function CYP2D6 alleles are gene duplications, which are not detected.
- What the research suggests
- No genotype-based adjustment. MDMA has no approved medical use; if exposure occurs, monitor body temperature, blood pressure and neurological status.
About MDMA
MDMA is a substituted amphetamine that forces the release of serotonin, dopamine and noradrenaline.
Others in other substances
Compare all 7 other substancesDon't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.